表紙
市場調査レポート

千寿製薬 : 製品パイプライン分析

Senju Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 305187
出版日 ページ情報 英文 35 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
千寿製薬 : 製品パイプライン分析 Senju Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015
出版日: 2015年11月18日 ページ情報: 英文 35 Pages
概要

千寿製薬は、五感(耳、目、鼻、のど、皮膚)用の医薬品を研究開発から製造販売まで一貫して行っている専門的製薬会社です。同社は特に眼科製品では専門性が高く、製品ポートフォリオには処方薬をはじめ、店頭販売薬、動物化学薬などを提供し、治療分野は多岐に渡っています。

当レポートでは、千寿製薬における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

千寿製薬の基本情報

  • 千寿製薬の概要
  • 主要情報
  • 企業情報

千寿製薬:R&Dの概要

  • 主な治療範囲

千寿製薬:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

千寿製薬:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

千寿製薬:薬剤プロファイル

  • bromfenac sodium
  • SJP-0118
  • SJP-0129
  • difluprednate
  • fonadelpar
  • SNJ-1656
  • SUN-131
  • SJP-0008
  • SNJ-1945

千寿製薬:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

千寿製薬:最近のパイプライン動向

千寿製薬:休止中のプロジェクト

千寿製薬:企業発表

千寿製薬:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07766CDB

Summary

Global Markets Direct's, 'Senju Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Senju Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Senju Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Senju Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Senju Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Senju Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Senju Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Senju Pharmaceutical Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Senju Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Senju Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Senju Pharmaceutical Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Senju Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Senju Pharmaceutical Co., Ltd. Snapshot
    • Senju Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Senju Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Senju Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Senju Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Senju Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Senju Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Senju Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Senju Pharmaceutical Co., Ltd. - Drug Profiles
    • bromfenac sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SJP-0118
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SJP-0129
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • difluprednate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fonadelpar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SNJ-1656
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SUN-131
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SJP-0008
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SNJ-1945
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Senju Pharmaceutical Co., Ltd. - Pipeline Analysis
    • Senju Pharmaceutical Co., Ltd. - Pipeline Products by Target
    • Senju Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
    • Senju Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
    • Senju Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Senju Pharmaceutical Co., Ltd. - Recent Pipeline Updates
  • Senju Pharmaceutical Co., Ltd. - Dormant Projects
  • Senju Pharmaceutical Co., Ltd. - Company Statement
  • Senju Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Senju Pharmaceutical Co., Ltd., Key Information
  • Senju Pharmaceutical Co., Ltd., Key Facts
  • Senju Pharmaceutical Co., Ltd. - Pipeline by Indication, 2015
  • Senju Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
  • Senju Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Senju Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2015
  • Senju Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • Senju Pharmaceutical Co., Ltd. - Phase III, 2015
  • Senju Pharmaceutical Co., Ltd. - Phase II, 2015
  • Senju Pharmaceutical Co., Ltd. - Phase I, 2015
  • Senju Pharmaceutical Co., Ltd. - Preclinical, 2015
  • Senju Pharmaceutical Co., Ltd. - Pipeline by Target, 2015
  • Senju Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2015
  • Senju Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2015
  • Senju Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Senju Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2015
  • Senju Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2015
  • Senju Pharmaceutical Co., Ltd., Other Locations
  • Senju Pharmaceutical Co., Ltd., Subsidiaries

List of Figures

  • Senju Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • Senju Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
  • Senju Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Senju Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2015
  • Senju Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2015
  • Senju Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Senju Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Senju Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top